Abbvie Inc ABBV

$294.55 -0.48 (-0.16%)

Valuation

Market cap
521,499,712,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
P/E (trailing)
22.95
P/E (forward)
21.06
Profit margin
6.91%
Debt to equity
-17.83

Trading

Volume
5,493,700
Avg volume
4,967,088
Day's range
$293.97 – $301.20
Shares out
1,767,616,000
Stochastic %K
62%
Beta
0.20
Analysts
Moderate Buy
Price target
$309.60

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

55X_ROI_Q1_2026 Nov 17, 6:27 AM
$SLS Onureg - BAT for CR1 remission 24.7 month MOS. • Adding Venetoclax FAILED to increase OS in 5 large trials - including the VIALE-M CR1 Remission P3 trial conducted by $ABBV. • Gps Phase 2 MOS in CR1 was not reached > 67.6 months - in the same exact setting. 67.6 Months w Gps vs 24.7 Months w BAT in CR1 ///
0 replies
Techdamentals Nov 17, 1:17 AM
The S&P 500 fell 1.92% to 7,416.59 on Monday, November 16, 2026, its third straight loss, as a heavy week of earnings gets going. One number from $ABBV's latest report: net revenues rose 10.3% to $17.404 billion in the quarter ended September 30, 2026, from $15.776 billion a year earlier. Is it growing, does it make money, can it pay its bills? The Techdamentals IV Calculator lays out revenue, margins, cash and debt from the company's own reported numbers. See the fundamentals for yourself and sign up for free. Educational, not advice. https://techdamentals.com/v3/ABBV?ref=st
0 replies
55X_ROI_Q1_2026 Nov 16, 11:38 PM
$SLS Phase 3 Results ARE COMING. THEY ARE NOW IMMINENT. and just the CR2/3 AML P3 Setting is WORTH A Shit Ton F More than the current manipulated $8.40 Share Price. and the Real, Reality is GPS Value will INCLUDE the CR1 Market As well. Gps Phase 3 results for CR2/3 Patients ~ 34 -36 month MOS is Longer than the Current Standard of Care for CR1 24.7 Months. and we have GPS Phase 2 CR1 Trial Results: > 67.6 Month MOS in CR1... SOC / Onureg is only 24.7 ADDING Venetoclax to Onureg FAILED - VEN + ONUREG FAILED TO INCREASE OS IN 5 LARGE TRIALS, Including Failing the VIALE-M P3 for CR1 conducted by $ABBV. ///
1 replies
55X_ROI_Q1_2026 Nov 16, 11:22 PM
$SLS $MRNA $XBI when you do the MATH: Just the Initial Phase 3 AML CR2/3 Indication is worth $120 Per Share . . Market Manipulation offering the investment opportunity of our lifetimes. and the Real Reality is GPS Value will INCLUDE the CR1 Market As well. Gps Phase 3 results for CR2/3 Patients ~ 34 -36 month MOS is Longer than the Current Standard of Care for CR1 24.7 Months. and we have GPS Phase 2 CR1 Trial Results: > 67.6 Month MOS in CR1... SOC / Onureg is only 24.7 ADDING Venetoclax to Onureg FAILED - VEN + ONUREG FAILED TO INCREASE OS IN 5 LARGE TRIALS, Including Failing the VIALE-M P3 for CR1 conducted by $ABBV. //
0 replies
openclassaction2 Nov 16, 10:52 PM
$ABBV a suit alleges abbvie failed to warn juvederm fillers can cause delayed granulomas, per open class actions. lawsuit stage, nothing to claim
0 replies
AnalystNick222 Nov 16, 9:00 PM
$ABBV 💊 ABBV: AbbVie is supported by its immunology, aesthetics, neuroscience, and oncology businesses. 📈 Key Catalysts: 🧪 New drug launches 💉 Immunology demand ✨ Aesthetics growth 🔬 Research pipeline A diversified pharmaceutical portfolio continues to support AbbVie’s long-term outlook.
0 replies
phoenixblaze Nov 16, 8:10 PM
$CYDY only green today is $CYDY .$LLY, $ABBV, $AMGN
0 replies
SellasgpsCurativeBAT11 Nov 16, 6:13 PM
$ABBV $BMY $JNJ $PFE $SLS Part 2. "....Michael Anglestein, a senior respiratory biologics sales specialist at AstraZeneca, then turned the conversation to Sellas' galinpepimut-S (GPS). "The REGAL Phase 3 trial for AML is a game changer for CR1 & CR2 patients," Anglestein said. "The trial has been going on for 5 1/2 years with no futility and very few side effects." ..." that GPS and Sellas' other clinical candidate, SLS009, would be "game changers" for AML and potentially other cancers..." Rob Tomko, a medical-device industry executive, agreed. "Going to be an absolute blockbuster once the results come out," Tomko said. "I couldn't agree moreịẠại A Stocktwits user also highlighted a LinkedIn comment attributed to Michael Frascello, a product director at Johnson & Johnson, that appears to have since been deleted. "Agree Sellas GPS and REGAL will be a game changer for AML care," Frascello reportedly said...' ✌️🙏❤️‍🩹
1 replies